Skip to content

Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers

Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02789033
Enrollment
68
Registered
2016-06-02
Start date
2015-06-30
Completion date
2015-08-31
Last updated
2021-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcers

Keywords

diabetic foot ulcers, chitosan, isosorbide dinitrate spray

Brief summary

The prevalence of diabetic foot ulceration in the diabetic population is 4-10%; the condition is more frequent in elder patients. It is estimated that about 5% of all patients with diabetes present a history of foot ulceration, while the lifetime risk of diabetic patients developing this complication is 15%. The majority (60-80%) of foot ulcers will heal, while 10-15% of them will remain active, and 5-24% of them will finally lead to limb amputation within a period of 6-18 months after the first evaluation , 2 out of 3 patients with a limb amputation could also be involved in a new amputation in the next year; higher or in the other leg , Eighty-five percent of lower-limb amputations in patients with diabetes are preceded by foot ulceration. The management of chronic diabetic foot ulcers (DFU) suggests multi-disciplinary approaches including control of diabetes, orthotic shoe wear, off-loading device, wound care and surgery in selected cases. However, treatment of DFU remains challenging because of unsatisfactory results from surgical and non-surgical treatments. Many adjunctive therapies are designed to improve the care of DFU including negative pressure wound therapy , ultrasound, recombinant human platelet-derived growth factor-BB (rPDGF-BB) Hyperbaric oxygen and acellular matrix product among others.

Detailed description

A randomized, placebo controlled, double-blind Clinical trial was designed. 60 Patients with diabetic foot ulcers in grade I and II of the classification of Wagner, with leg arm index\> 0.8 and without specific treatment for foot ulcers referred to the experimental and clinical Therapeutic Institute will be included. All patients give written informed consent; previously the protocol was approved for the bioethics committee of the CUCS, of the Guadalajara University, registration number 030-2010. Patients with another type of topical medication will be excluded. Isosorbide dinitrate spray (2.5 mg). Preparation of chitosan Hydrogels: The composition of gel formulation will be given prior training. ISDN and chitosan gel will be applied handled under aseptic conditions to the wound, and covered with sterile bandages. The patients will be evaluated every 2 weeks (macroscopic study and measurement of the ulcerated area) until 6 views. A second biopsy will be done one week before the finalization of the treatment of 15 weeks. The biopsies will be embedded on paraformaldehyde (4%) and paraffin. Sections of 5 µm were analyzed by a pathologist to determine hypertrophic and hyperplasic capillaries, inflammation and cellular matrix using Hematoxylin & eosin and Masson's trichrome stains. An immunohistochemical stain was also realized to evaluate several molecular markers such as α-SMA (abcam, Cambridge, MA), Desmin (abcam, Cambridge, MA), VEGF (abcam, Cambridge, MA) and Von Willebrand Factor (Chemicon, CA). (figure 1) Statistical analysis: It will be done using SPSS program for Windows Version 10.0, the results of quantitative variables were expressed in average and standard deviation. The differences between baseline and subsequent pharmacologic intervention measurements will be investigated with the Wilcoxon test. The Mann Whitney U test will be used to compare groups. Frequencies by categories as well as percentages will be quantified for qualitative variables. Comparisons between groups were performed with Chi2. For all comparisons p \< 0.05 will be considered as significant.

Interventions

Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine

Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate

DRUGPlacebo

placebo

Sponsors

University of Guadalajara
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with diabetic foot ulcers in grade I and II of the classification of Wagner * with leg arm index\> 0.8 and * without specific treatment for foot ulcers referred to the experimental and clinical

Exclusion criteria

* Patients with another type of topical medication * patients with diabetic foot ulcers in grade III and * with leg arm index \<0.8

Design outcomes

Primary

MeasureTime frameDescription
Biopsies75 daysHistological changes in ulcers

Participant flow

Pre-assignment details

ADDITIONAL PARTICIPANTS WERE INCLUDED ANTICIPATING PARTICIPANTS WHO DO NOT COMPLETE THE CLINICAL TRIAL

Participants by arm

ArmCount
Active Comparator: Chitosan
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine And Placebo in the same pharmacological presentation that Isosorbide dinitrate spray
17
Active Comparator: Isosorbide Dinitrate Spray
Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate. And Placebo in the same pharmacological presentation that Chitosan
17
Combination: IDS and Chitosan
Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate. And Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
17
Placebo Comparator: Placebo
Placebo in the same pharmacological presentation that both, IDS and Chitosan.
17
Total68

Baseline characteristics

CharacteristicActive Comparator: ChitosanActive Comparator: Isosorbide Dinitrate SprayCombination: IDS and ChitosanPlacebo Comparator: PlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
17 Participants17 Participants17 Participants17 Participants68 Participants
Diameter of the ulcer10.5 centimeters
STANDARD_DEVIATION 5.8
12.1 centimeters
STANDARD_DEVIATION 7
11.4 centimeters
STANDARD_DEVIATION 8.2
15.8 centimeters
STANDARD_DEVIATION 9.3
12.3 centimeters
STANDARD_DEVIATION 7.5
Sex: Female, Male
Female
8 Participants8 Participants8 Participants8 Participants32 Participants
Sex: Female, Male
Male
9 Participants9 Participants9 Participants9 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 170 / 170 / 170 / 17
other
Total, other adverse events
0 / 170 / 170 / 170 / 17
serious
Total, serious adverse events
0 / 170 / 170 / 170 / 17

Outcome results

Primary

Biopsies

Histological changes in ulcers

Time frame: 75 days

ArmMeasureGroupValue (MEAN)Dispersion
Active Comparator: ChitosanBiopsiesα-smooth muscle actin2.46 UI/dLStandard Deviation 0.6
Active Comparator: ChitosanBiopsiesVon Willebrand Factor2.38 UI/dLStandard Deviation 0.65
Active Comparator: ChitosanBiopsiesvascular endothelial growth factor-A2.23 UI/dLStandard Deviation 0.8
Active Comparator: ChitosanBiopsiesdesmin2.3 UI/dLStandard Deviation 0.8
Active Comparator: Isosorbide Dinitrate SprayBiopsiesdesmin2.5 UI/dLStandard Deviation 0.6
Active Comparator: Isosorbide Dinitrate SprayBiopsiesvascular endothelial growth factor-A2.6 UI/dLStandard Deviation 0.6
Active Comparator: Isosorbide Dinitrate SprayBiopsiesVon Willebrand Factor2.28 UI/dLStandard Deviation 0.82
Active Comparator: Isosorbide Dinitrate SprayBiopsiesα-smooth muscle actin2.64 UI/dLStandard Deviation 0.6
Combination: IDS and ChitosanBiopsiesvascular endothelial growth factor-A2.43 UI/dLStandard Deviation 0.6
Combination: IDS and ChitosanBiopsiesdesmin2.6 UI/dLStandard Deviation 0.6
Combination: IDS and ChitosanBiopsiesVon Willebrand Factor2.31 UI/dLStandard Deviation 0.8
Combination: IDS and ChitosanBiopsiesα-smooth muscle actin2.56 UI/dLStandard Deviation 0.6
Placebo Comparator: PlaceboBiopsiesVon Willebrand Factor2.15 UI/dLStandard Deviation 0.5
Placebo Comparator: PlaceboBiopsiesα-smooth muscle actin2.07 UI/dLStandard Deviation 0.6
Placebo Comparator: PlaceboBiopsiesdesmin2.3 UI/dLStandard Deviation 0.6
Placebo Comparator: PlaceboBiopsiesvascular endothelial growth factor-A2.07 UI/dLStandard Deviation 0.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026